Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial

British Journal of Cancer

Volumn 97, Issue 2, 2007, Pages 152-161

  Mansel, R ^a   Locker, G ^b   Fallowfield, L ^c   Benedict, A ^d   Jones, D ^e  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b Evanston Northwestern Healthcare ^*  (United States)

^c BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

^d MEDTAP International Inc   (United Kingdom)

^e ASTRAZENECA   (United Kingdom)

Author keywords

Anastrozole; Aromatase inhibitor; Breast cancer; Cost effectiveness analysis; Cost utility analysis; Tamoxifen

Indexed keywords

ANASTROZOLE; GENERIC DRUG; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HEALTH CARE UTILIZATION; HUMAN; MEDICAL LITERATURE; POSTMENOPAUSE; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; RESOURCE ALLOCATION; STATISTICAL MODEL; TREATMENT DURATION; UNITED KINGDOM;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; FEMALE; GREAT BRITAIN; HUMANS; MIDDLE AGED; NITRILES; POSTMENOPAUSE; TAMOXIFEN; TREATMENT OUTCOME; TRIAZOLES;

EID: 34447326488     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603804     Document Type: Article

References (37)

1. ATAC Trialists' Group (2005) Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365: 60-62
2. Benedict Á, Christie A (2003) Budget impact analysis of anastrozole as adjuvant therapy in the treatment of early breast cancer in the UK [abstract]. Value Health 6: 735
3. Briggs A (2001) Handling uncertainty in economic evaluations and presenting the results. In Economic Evaluation in Health Care: Merging Theory with Practice Drummond M, McGuire AM (eds). Oxford University Press, Oxford, UK, pp 172-214
4. British National Formulary (2003/2004) Available at: http://www.bnf.org/ bnf.Accessed March 2003 and Sept 2004
5. Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A (2006) Quality of life of postmenopausal women in the ATAC ('Arimidex' tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Br Cancer Res Treat 100(3): 273-284
6. Cook PJ, Doll R, Fellingham SA (1969) A mathematical model for the age distribution of cancer in man. Int J Cancer 4: 93-112
7. Coyle D, Small N, Ashworth A, Hennessy S, Jenkins-Clarke S, Mannion R, Rice N, Ahmedzai S (1999) Costs of palliative care in the community, in hospitals and in hospices in the UK. Crit Rev Oncol Hematol 32: 71-85
8. Department of Health Reference costs (2003). London, UK
9. Early Breast Cancer Trialists' Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451-1467
10. Early Breast Cancer Trialists' Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival: an overview of the randomised trials. Lancet 365: 1687-1717
11. Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A (2004) Quality of life of postmenopausal women in the arimidex, tamoxifen, alone or in combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol 22: 4261-4271
12. Fisher B, Dignam J, Bryant J, Wolmark N (2001) Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93: 684-690
13. Gordois A, Posnett J, Borris L, Bossuyt P, Jonsson B, Levy E, de Pouvourville G (2003) The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopaedic surgery. J Thromb Haemost 1: 2167-2174
14. Hillner BE (2004) Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. Cancer 101: 1311-1322
15. Iglesias CP, Torgerson DJ, Bearne A, Bose U (2002) The cost utility of bisphosphonate treatment in established osteoporosis. Q J Med 95: 305-311
16. Kamby C, Sengeløv L (1997) Pattern of dissemination and survival following isolated locoregional recurrence of breast cancer. Breast Cancer Res Treat 45: 181-192
17. Karnon J, Brown J (2002) Tamoxifen plus chemotherapy versus tamoxifen alone as adjuvant therapies for node-positive postmenopausal women with early breast cancer: a stochastic economic evaluation. PharmacoEconomics 20: 119-137
18. Lamerato L, Havstad S, Gandhi SK, Jones DA (2004) The Economic Burden of Breast Cancer Recurrence: Findings from a Retrospective Analysis of Health System Data [abstract]. 27th Annual San Antonio Breast Cancer Symposium: San Antonio, TX
19. Locker GY, on behalf of the ATAC Trialists' Group (2004) Cost-utility analysis of anastrozole versus tamoxifen as primary adjuvant therapy in postmenopausal women with early breast cancer from a US healthcare system perspective: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial [abstract]. 27th Annual San Antonio Breast Cancer Symposium: San Antonio, TX
20. Love RR, Wiebe DA, Newcomb PA, Cameron L, Leventhal H, Jordan VC, Feyzi J, DeMets DL (1991) Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 115: 860-864
21. Monthly Index of Medical Specialties (MIMS) (2005) Haymarket Medical Limited. Available at: http://www.emims.net.Accessed January 2005
22. Moran M, Haffty B (2002) Local-regional breast cancer recurrence: prognostic groups based on patterns of failure. Breast J 8: 81-87
23. National Institute for Health and Clinical Excellence (2002) Guidance on the Use of Trastuzumab for the Treatment of Advance Breast Cancer. Technology Appraisal No. 34. National Institute for Health and Clinical Excellence: London, UK
24. National Institute for Health and Clinical Excellence (2003) Guidance on the use of imatinib for chronic myeloid leukaemia. Technology Appraisal No. 70. National Institute for Health and Clinical Excellence: London, UK
25. National Institute for Health and Clinical Excellence (2004) Guide to the Methods of Technology Appraisal. National Institute for Health and Clinical Excellence: London, UK
26. National Institute for Health and Clinical Excellence (2005) The Clinical Effectiveness and Cost Effectiveness of Prevention and Treatment of Osteoporosis. National Institute for Health and Clinical Excellence: London, UK. Available at: http://www.nice.org.uk/pdf/assessment_report_osteo.pdf (accessed June 23, 2005)
27. Office of National Statistics (2002) http://www.statistics.gov.uk/ downloads/theme_health/Dh2_29/DH2No29.pdf (accessed on October 18, 2004)
28. Peto R, Boreham J, Clarke M, Davies C, Beral V (2000) UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 355: 1822
29. Reddy P, Chow MS (2000) Safety and efficacy of antiestrogens for prevention of breast cancer. Am J Health Syst Pharm 57: 1315-1322
30. Sculpher M, Claxton K (2005) Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty - when is there sufficient evidence? Value in Health 8: 433-446
31. Sonnenberg FA, Beck JR (1993) Markov models in medical decision making: a practical guide. Med Decis Making 13: 322-338
32. Stockler M, Wilcken NR, Ghersi D, Simes RJ (2000) Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat Rev 26: 151-168
33. The ATAC Trialists' Group (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98: 1802-1810
34. Torrance GW (1986) Measurement of health state utilities for economic appraisal. J Health Econ 5: 1-30
35. Towse A, Pritchard C (2002) Does NICE have a threshold? An external view. In: Towse A, Pritchard C, Devlin N (eds). Cost-Effectiveness Thresholds: Economic and Ethical Issues pp 25-37. BSC Print Ltd: London
36. van Hout BA, Al MJ, Gordon GS, Rutten FF (1994) Costs, effects and C/E-ratios alongside a clinical trial. Health Econ 3: 309-319
37. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23: 619-629